Department of Research, Sir Ganga Ram Hospital, New Delhi-110060, India.
Gachon Institute of Pharmaceutical Science and Department of Pharmacy, College of Pharmacy, Gachon University, Incheon, Korea.
Curr Top Med Chem. 2021;21(8):696-704. doi: 10.2174/1568026620666201207100139.
Glioma predominantly targets glial cells in the brain and spinal cord. There are grade I, II, III, and IV gliomas with anaplastic astrocytoma and glioblastoma multiforme as the most severe forms of the disease. Current diagnostic methods are limited in their data acquisition and interpretation, markedly affecting treatment modalities, and patient outcomes. Circulating extracellular vesicles (EVs) or "magic bullets" contain bioactive signature molecules such as DNA, RNA, proteins, lipids, and metabolites. These secretory "smart probes" participate in myriad cellular activities, including glioma progression. EVs are released by all cell populations and may serve as novel diagnostic biomarkers and efficient nano-vehicles in the targeted delivery of encapsulated therapeutics. The present review describes the potential of EV-based biomarkers for glioma management.
神经胶质瘤主要靶向大脑和脊髓中的神经胶质细胞。神经胶质瘤分为 I 级、II 级、III 级和 IV 级,间变性星形细胞瘤和多形性胶质母细胞瘤是该疾病最严重的形式。目前的诊断方法在数据采集和解释方面存在局限性,显著影响了治疗方式和患者的预后。循环细胞外囊泡 (EVs) 或“神奇子弹”含有生物活性特征分子,如 DNA、RNA、蛋白质、脂质和代谢物。这些分泌的“智能探针”参与多种细胞活动,包括神经胶质瘤的进展。EVs 由所有细胞群释放,可作为新型诊断生物标志物,并作为封装治疗药物的靶向递释的有效纳米载体。本综述描述了基于 EV 的生物标志物在神经胶质瘤管理中的潜力。